These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21893261)

  • 1. [The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients].
    Sánchez-Pulgarín M; Martínez-de-la-Casa JM; Escalada A; Sáenz-Francés F; García-Feijoó J; García Sánchez J
    Arch Soc Esp Oftalmol; 2011 Sep; 86(9):282-6. PubMed ID: 21893261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination.
    Rossi GC; Pasinetti GM; Scudeller L; Tinelli C; Milano G; Bianchi PE
    Expert Opin Pharmacother; 2010 Mar; 11(4):499-504. PubMed ID: 20163264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
    Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
    Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.
    Okeke CO; Quigley HA; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Friedman DS
    Ophthalmology; 2009 Feb; 116(2):191-9. PubMed ID: 19084273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.
    Holló G; Kóthy P
    Curr Med Res Opin; 2008 Jun; 24(6):1755-61. PubMed ID: 18479590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational study of patients switched to the fixed travoprost 0.004%/timolol 0.5% combination in Croatia.
    Mandic Z; Novak-Lauš K; Bojic L; Popovic-Suic S; Maricic-Došen V; Pelcic G; Dobutovic D; Biuk D; Kovacic Z; Pavan J
    Methods Find Exp Clin Pharmacol; 2010 Oct; 32(8):593-8. PubMed ID: 21132129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%.
    Scherzer ML; Liehneova I; Negrete FJ; Schnober D
    Adv Ther; 2011 Aug; 28(8):661-70. PubMed ID: 21773673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Travoprost/timolol fixed combination.
    Herceg M; Noecker R
    Expert Opin Pharmacother; 2008 Apr; 9(6):1059-65. PubMed ID: 18377347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension.
    Suzuki ER; Franklin LM; da Silva LJ; Figueiredo CR; Netto JA; Batista WD
    Curr Med Res Opin; 2006 Sep; 22(9):1799-805. PubMed ID: 16968583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
    Flowers B; Wand M; Piltz-Seymour J; Berke SJ; Day D; Teague J; Smoot TM; Landry TA; Bergamini MV; Mallick S;
    Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma.
    Holló G; Kóthy P; Géczy A; Vargha P
    J Glaucoma; 2009; 18(4):288-92. PubMed ID: 19365193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
    Chiseliţă D; Antohi I; Medvichi R; Danielescu C
    Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life experience study of the safety and efficacy of travoprost 0.004% / timoptol 0.50% fixed combination ophthalmic solution in intraocular pressure control.
    Olali C; Malietzis G; Ahmed S; Samaila E; Gupta M
    Niger J Clin Pract; 2011; 14(1):29-33. PubMed ID: 21493988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension.
    Pachimkul P; Yuttitham K; Thoophom P
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S81-7. PubMed ID: 21717884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.